Loading stock data…
GMED
$82.52+4.22 (+5.39%)
Market ClosedLast close Jun 9
Globus Medical, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Globus Medical, Inc. in the Healthcare sector is trading at $82.52 with a market capitalization of $10.6B. Wall Street consensus targets $110.00 (11 analysts), implying a +33.3% move over the next 12 months. The stock is currently 19% below its 52-week high of $101.40, remaining 2.8% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +33.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$82.52
Potential Upside
56.8%
Whystock Fair Value$129.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$110.00+33.3%
Range$87.00 – $122.00
Fundamentals
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle scre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.21
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.40%
Volume
Today's trading volume
1.48M
Recent News
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
Globus Medical is riding on musculoskeletal market growth with strong Q1 sales gains, double-digit spine growth, and rising trauma demand across key product lines.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD gains from acquisition-led Residential Care Software growth, mask innovation and strong finances but faces macro and competitive pressures.
2 Reasons to Watch GMED and 1 to Stay Cautious
Over the past six months, Globus Medical’s shares (currently trading at $79.99) have posted a disappointing 10.1% loss, well below the S&P 500’s 10.7% gain. This might have investors contemplating their next move.
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.